UK markets closed

ArriVent BioPharma, Inc. (AVBP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
20.10-0.05 (-0.25%)
At close: 04:00PM EDT
20.62 +0.52 (+2.59%)
After hours: 06:51PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 674.90M
Enterprise value 357.79M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)2.12
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 30.75%
S&P500 52-week change 326.36%
52-week high 325.95
52-week low 314.35
50-day moving average 317.64
200-day moving average 318.86

Share statistics

Avg vol (3-month) 3172.63k
Avg vol (10-day) 338.56k
Shares outstanding 533.49M
Implied shares outstanding 633.49M
Float 818.71M
% held by insiders 113.68%
% held by institutions 165.21%
Shares short (30 Apr 2024) 41.61M
Short ratio (30 Apr 2024) 410.67
Short % of float (30 Apr 2024) 46.66%
Short % of shares outstanding (30 Apr 2024) 44.81%
Shares short (prior month 28 Mar 2024) 4734.76k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-19.72%
Return on equity (ttm)-30.31%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-74.58M
Diluted EPS (ttm)N/A
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)317.39M
Total cash per share (mrq)9.48
Total debt (mrq)285k
Total debt/equity (mrq)0.09%
Current ratio (mrq)32.82
Book value per share (mrq)N/A

Cash flow statement

Operating cash flow (ttm)-57.59M
Levered free cash flow (ttm)-48.18M